» Articles » PMID: 33842661

Human Cutaneous B Cells: What Do We Really Know?

Overview
Journal Ann Transl Med
Date 2021 Apr 12
PMID 33842661
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

B cells play many critical roles in the systemic immune response, including antibody secretion, antigen presentation, T cell co-stimulation, and pro- and anti-inflammatory cytokine production. However, the contribution of B cells to the local immune response in many non-lymphoid tissues, such as the skin, is incompletely understood. Cutaneous B cells are scarce except in certain malignant and inflammatory conditions, and as such, have been poorly characterized until recently. Emerging evidence now suggests an important role for cutaneous B in both skin homeostasis and pathogenesis of skin disease. Herein, we discuss the potential mechanisms for cutaneous B cell recruitment, localized antibody production, and T cell interaction in human skin infections and primary skin malignancies (i.e., melanoma, squamous cell carcinoma). We further consider the likely contribution of cutaneous B cells to the pathogenesis of inflammatory skin diseases, including pemphigus vulgaris, lupus erythematosus, systemic sclerosis, hidradenitis suppurativa, and atopic dermatitis. Finally, we examine the feasibility of B cell targeted therapy in the dermatologic setting, emphasizing areas that are still open to investigation. Through this review, we hope to highlight what we really know about cutaneous B cells in skin, which can sometimes be lost in reviews that more broadly incorporate extensive data from animal models.

Citing Articles

From neglect to spotlight: the underappreciated role of B cells in cutaneous inflammatory diseases.

Lee E, Oh J Front Immunol. 2024; 15:1328785.

PMID: 38426103 PMC: 10902158. DOI: 10.3389/fimmu.2024.1328785.


The Distinctive Features behind the Aggressiveness of Oral and Cutaneous Squamous Cell Carcinomas.

Alonso-Juarranz M, Mascaraque M, Carrasco E, Gracia-Cazana T, de la Sen O, Gilaberte Y Cancers (Basel). 2023; 15(12).

PMID: 37370836 PMC: 10296732. DOI: 10.3390/cancers15123227.


Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions.

Niebel D, de Vos L, Fetter T, Bragelmann C, Wenzel J Am J Clin Dermatol. 2023; 24(4):521-540.

PMID: 37140884 PMC: 10157137. DOI: 10.1007/s40257-023-00774-8.


Promising Natural Products in New Drug Design, Development, and Therapy for Skin Disorders: An Overview of Scientific Evidence and Understanding Their Mechanism of Action.

Mohd Zaid N, Sekar M, Bonam S, Gan S, Lum P, Begum M Drug Des Devel Ther. 2022; 16:23-66.

PMID: 35027818 PMC: 8749048. DOI: 10.2147/DDDT.S326332.


Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis.

Kader H, Azeem M, Jwayed S, Al-Shehhi A, Tabassum A, Ayoub M Cells. 2021; 10(6).

PMID: 34200009 PMC: 8226506. DOI: 10.3390/cells10061392.

References
1.
Whitfield M, Finlay D, Murray J, Troyanskaya O, Chi J, Pergamenschikov A . Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A. 2003; 100(21):12319-24. PMC: 218756. DOI: 10.1073/pnas.1635114100. View

2.
Xie Y, Jinnin M, Zhang X, Wakasugi S, Makino T, Inoue Y . Immunohistochemical characterization of the cellular infiltrate in discoid lupus erythematosus. Biosci Trends. 2011; 5(2):83-8. DOI: 10.5582/bst.2011.v5.2.83. View

3.
Timmermans W, van Laar J, van Hagen P, van Zelm M . Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology. 2017; 5(12):e118. PMC: 5192066. DOI: 10.1038/cti.2016.75. View

4.
Simon D, Hosli S, Kostylina G, Yawalkar N, Simon H . Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol. 2008; 121(1):122-8. DOI: 10.1016/j.jaci.2007.11.016. View

5.
Chong B, Tseng L, Kim A, Miller R, Yancey K, Hosler G . Differential expression of BAFF and its receptors in discoid lupus erythematosus patients. J Dermatol Sci. 2013; 73(3):216-24. PMC: 3946198. DOI: 10.1016/j.jdermsci.2013.11.007. View